How to Assess the High Risk of Pharmaceutical Leaders and New Energy Leaders

High-valued pharmaceutical stocks represented by Hengrui should pay attention to chasing high risks; the CXO sector should pay attention to cyclical risks in about a year or two (2020.11)

Disclaimer:

This video strives but does not guarantee the accuracy and completeness of the content, nor should readers assume that the information is accurate and complete. In no event does the information or opinions expressed in this video constitute investment advice to anyone. Readers should consider whether any opinion or advice in this video is appropriate for their particular situation, and should seek expert advice if necessary. The information, tools, opinions and speculations contained in this video are for informational purposes only and are not intended or deemed to be an invitation or invitation to sell or buy securities or other investment subjects.

$BYD(SZ002594)$ $Pien Tze Huang(SH600436)$ $Hengrui Medicine(SH600276)$

This topic has 0 discussions in Snowball, click to view.
Snowball is an investor’s social network, and smart investors are here.
Click to download Snowball mobile client http://xueqiu.com/xz ]]>

This article is reproduced from: http://xueqiu.com/1472391509/231978333
This site is for inclusion only, and the copyright belongs to the original author.